Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 5 6 7 8 9 … 54 Next »

Effectiveness of (IL)-17A to other biologics in patients with psoriasis

Threaded Mode
Effectiveness of (IL)-17A to other biologics in patients with psoriasis
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,918
Threads: 3,887
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#1
News  Thu-30-06-2022, 16:42 PM
This study compared the effectiveness of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis.

Quote:
Background:
Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice.

Objectives:
To compare the effectiveness of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis.

Methods:
The Psoriasis Study of Health Outcomes (PSoHO) is an ongoing 3-year observational cohort study in adults with chronic moderate-to-severe plaque psoriasis initiating or switching to a new biologic. Primary study endpoint is proportion of patients achieving 90% improvement in Psoriasis Area and Severity Index (PASI 90) and/or static Physician Global Assessment (sPGA) 0/1 at Week 12 (W12) in the anti-IL-17A cohort (ixekizumab [IXE], secukinumab) versus all other approved biologics. Secondary outcomes include proportion of patients who achieve PASI 75/90/100, absolute PASI scores ≤5, ≤2 and ≤1, Dermatology Life Quality Index (DLQI) score of 0/1 at W12 between the two cohorts and among the individual biologics. Comparative effectiveness analyses were conducted using Frequentist Model Averaging (FMA), a novel causal inference machine learning approach. Missing data for binary outcomes were imputed as non-response.

Results:
Patient profiles in the anti-IL-17A cohort and other biologics cohort were similar, with more frequent comorbid psoriatic arthritis and less frequent exposure to conventional treatments in the patients receiving anti-IL17A biologics. At W12, 71.4% of patients who received an anti-IL-17A biologic achieved PASI 90 and/or sPGA 0/1 compared to 58.6% of patients who received other biologics (odds ratios [OR], 1.9; 95% confidence intervals [CI], [1.6, 2.4]). Similar findings were observed for secondary outcomes.

Conclusions:
These results reflect the high efficacy and early onset of skin clearance of IL-17A inhibitors observed in randomized clinical trials and confirm the effectiveness of anti-IL17A biologics in the real-world setting.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Biological Treatments For Psoriasis
Quote
KatT Offline
100 + Member I Just Cant Stop !

100 + Member I Just Cant Stop !
Posts: 5,775
Threads: 50
Joined: Sep 2019
Gender: Female
Location: Canada
Psoriasis Score: 1
Psoriatic Arthritis Score: Off the chart!
Treatment: Simponi + hydroxychloroquine + MTX
#2
Fri-01-07-2022, 06:04 AM
Interesting! Wonder if they will do a similar study for PSA.  I find it more difficult to treat than the psoriasis.

I did take Cosentyx buuut didn't see improvement in PSA.  As for it's effectiveness on psoriasis, I was also taking azathioprine at the same time so it's hard to tell which medication was more efficient.
Quote
Caroline Offline
You must hurry if you ever want to catch a chicken...
*
Forum Helper
Posts: 26,500
Threads: 113
Joined: Nov 2011
Gender: Female
Location: In between the tulips
Psoriasis Score: 3
Psoriatic Arthritis Score: 3
PQOLS: 4
Treatment: Got back to DMF slow release
#3
Fri-01-07-2022, 06:39 AM
Agreed KatT and this even while IL-17 is known as an indicator for Psoriatic Arthritis, where treatments of IL-17 often seem to work.
You are an exception with the Cosentyx, which has a good name for treating Psoriatic Arthritis.

While Psoriatic Arthritis is seen in 30% of the Psoriasis patients, it doesn’t seem to have an equal 30% in research.
Quote
Fred Offline Author
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,918
Threads: 3,887
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#4
Fri-01-07-2022, 11:57 AM
(Fri-01-07-2022, 06:04 AM)KatT Wrote: Interesting! Wonder if they will do a similar study for PSA.  I find it more difficult to treat than the psoriasis.

I would imagine so, my doctor has suggested it as my next treatment.

Bimzelx psoriatic arthritis phase 3 results
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Does smoking affect psoriasis biologics Fred 3 683 Tue-04-03-2025, 21:39 PM
Last Post: Caroline
News Effectiveness of Tremfya in patients with facial and/or genital psoriasis Fred 0 1,342 Fri-28-06-2024, 13:10 PM
Last Post: Fred
News Persistence and effectiveness of Tremfya in Spanish psoriasis patients Fred 0 2,170 Sat-12-08-2023, 13:53 PM
Last Post: Fred
News Atopic like dermatitis induced by IL-17A inhibitors for psoriasis Fred 1 2,259 Wed-02-08-2023, 20:20 PM
Last Post: Caroline
News Ilumetri / Ilumya real-world effectiveness and safety Fred 0 1,616 Wed-07-09-2022, 14:42 PM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    About | Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2025 Psoriasis Club | All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode